Trinity Biotech (TRIB) Cash from Discontinued Operations (2023 - 2024)
Trinity Biotech's (TRIB) quarterly Cash from Discontinued Operations came in at $8.8 million in Q4 2024, down 26.79% year-over-year from $12.0 million in Q1 2024, and up 341.35% quarter-over-quarter from -$3.6 million in Q3 2024.
Powered by 
Analysis
Trinity Biotech (TRIB) Cash from Discontinued Operations (2023 - 2024) Analysis & Trends
Trinity Biotech has disclosed Cash from Discontinued Operations across 2 years of filings, most recently posting $8.8 million for Q4 2024.
- In Q4 2024, Cash from Discontinued Operations fell 26.79% year-over-year to $8.8 million; the TTM figure through Dec 2024 stood at $12.1 million (changed N/A YoY), while the FY2023 annual figure was -$177000.0, changed N/A from the prior year.
- Cash from Discontinued Operations came in at $8.8 million for Q4 2024 at Trinity Biotech, up from -$3.6 million in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of $12.0 million in Q4 2023 to a low of -$5.1 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 29.78 Bn | 27.67 Bn | 2.18 Bn | - |
| 2 | Lantheus Holdings | 6.58 Bn | 5.99 Bn | 241.86 Mn | - |
| 3 | Heartflow | 4.11 Bn | 3.74 Bn | 53.19 Mn | - |
| 4 | Neogen | 2.60 Bn | 2.41 Bn | 107.80 Mn | - |
| 5 | Butterfly Network | 1.99 Bn | 1.86 Bn | 23.29 Mn | - |
| 6 | Ceribell | 921.90 Mn | 792.63 Mn | 25.94 Mn | - |
| 7 | QuidelOrtho | 886.88 Mn | 763.48 Mn | - | - |
| 8 | Varex Imaging | 779.06 Mn | 679.86 Mn | 76.70 Mn | - |
| 9 | Prenetics Global | 338.37 Mn | 279.32 Mn | 30.20 Mn | - |
| 10 | Trinity Biotech | 5.83 Mn | 5.83 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 8.79 Mn |
| Sep 30, 2024 | -3.64 Mn |
| Dec 31, 2023 | 12.00 Mn |
| Sep 30, 2023 | -5.07 Mn |